Management of haematological malignancy in pregnancy

被引:9
作者
El-Hemaidi, Ihab [2 ]
Robinson, Susan E. [1 ]
机构
[1] Guys Hosp, Guys & St Thomas NHS Fdn Trust, Dept Haematol, London SE1 9RT, England
[2] Queen Elizabeth Hosp, Dept Haematol, London, England
关键词
lymphoma; leukaemia; chemotherapy; radiotherapy; pregnancy; myeloproliferative disorders; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; NON-HODGKINS-LYMPHOMA; TYROSINE KINASE JAK2; TRANS-RETINOIC ACID; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; ACTIVATING MUTATION; IN-UTERO;
D O I
10.1016/j.bpobgyn.2011.10.007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The incidence of haematological malignancies in pregnancy ranges from 1 in 1000 to 1 in 10,000. International prospective epidemiology, management and outcome data are important to gain further knowledge of haematological malignancies in pregnancy. The management of haematological malignancies in pregnancy is complex and requires a multidisciplinary approach. The clinician and mother need to address both maternal and fetal well-being. The mother should be provided with the necessary information and support to make informed decisions regarding the pregnancy and disease management. The haematological malignancies are a diverse group with varied presenting features, pathophysiology, treatment options, levels of urgency to commence treatment in pregnancy, effect on maternal and fetal outcome and overall prognosis. We have reviewed the published research in this area, and provide concise up-to-date guidance on the management of haematological malignancies in pregnancy. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 160
页数:12
相关论文
共 93 条
  • [1] Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregancy:: a case report and review of the literature
    Ali, R
    Özkalemkas, F
    Özkocaman, V
    Özçelik, W
    Ozan, U
    Kimya, Y
    Tunali, A
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (04) : 215 - 217
  • [2] Ali R, 2009, Leuk Res, V33, pe26, DOI 10.1016/j.leukres.2008.07.010
  • [3] Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    Alvarez-Larran, Alberto
    Cervantes, Francisco
    Pereira, Arturo
    Arellano-Rodrigo, Eduardo
    Perez-Andreu, Virginia
    Hernandez-Boluda, Juan-Carlos
    Ayats, Ramon
    Salvador, Carlos
    Muntanola, Ana
    Bellosillo, Beatriz
    Vicente, Vicente
    Hernandez-Nieto, Luis
    Burgaleta, Carmen
    Xicoy, Blanca
    Besses, Carlos
    [J]. BLOOD, 2010, 116 (08) : 1205 - 1210
  • [4] [Anonymous], CANC RES
  • [5] Pregnancy among patients with chronic myeloid leukemia treated with imatinib
    Ault, P
    Kantarjian, H
    O'Brien, S
    Faderl, S
    Beran, M
    Rios, MB
    Koller, C
    Giles, F
    Keating, M
    Talpaz, M
    Cortes, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1204 - 1208
  • [6] Hematological malignancies and pregnancy:: A final report of 84 children who received chemotherapy in utero
    Avilés, A
    Neri, N
    [J]. CLINICAL LYMPHOMA, 2001, 2 (03): : 173 - 177
  • [7] Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors
    Azim, Hatem A., Jr.
    Pavlidis, Nicholas
    Peccatori, Fedro A.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 (02) : 110 - 121
  • [8] Barbui T, 2004, HAEMATOLOGICA, V89, P215
  • [9] Barbui Tiziano, 2006, Hematology Am Soc Hematol Educ Program, P246
  • [10] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061